Nobel Biocare Science Newsletter – Volume 1, Issue 2, 2026
Circulation – 2,000 copies in various languages worldwide
To order a printed copy of the science newsletter
Please contact our customer service team or contact your sales representative.
Compromised patients and dental implants: Where evidence, integrity and human-centered care meet
Clinical complexity is the new normal
As populations age and chronic diseases become more prevalent, dental professionals are more frequently treating patients with complex medical histories such as cardiovascular disease, diabetes, cancer, osteoporosis, dementia or combinations of each.
For these patients, oral rehabilitation is not elective; it directly affects nutrition, communication, social participation, and ultimately their overall health and quality of life. At the same time, this growing complexity places a significant cognitive and emotional burden on practitioners, who must make challenging clinical decisions under time pressure and increasing professional demands.
No “average” compromised patient
Medically compromised patients are highly heterogeneous. They differ in systemic conditions, disease control, medication profiles, bone biology, healing capacity and risk tolerance. Oversimplifying this diversity through generalized success claims or messaging does not reflect clinical reality and increases the risk of misdiagnosis. Integrity in clinical communication is therefore not an abstract ideal; it is necessary discipline and a practical safeguard against potential misinterpretation and unintended consequences.
What the evidence really shows
Decades of research demonstrate that implant therapy can be successful in many compromised patients when appropriate case selection, careful planning, and biologically respectful protocols are applied.
At the same time, the evidence is clear: success is never guaranteed. Recognizing limitations is not a weakness of science, but a prerequisite for responsible clinical decision making.
Reducing risk through biology and evidence
This places a clear responsibility on manufacturers and scientific partners. In complex patient populations, clinicians must be able to rely on solutions supported by transparent, long-term evidence and independent validation.
Premium systems are defined not by claims of universality, but by robust data and openness about both strengths and limitations. Evidence also supports the importance of gentle, biologically respectful surgical protocols, minimizing trauma and preserving tissue vitality, particularly in patients with compromised healing capacity. Real-world evidence enhances controlled trials by reflecting everyday clinical practice and supporting decisions grounded in data rather than assumptions.
In this issue: Translating evidence into daily practice
This edition of the Science Newsletter is dedicated to how evidence, judgment, and communication converge in the care of compromised patients: An interview with Dr. Pedro Peña explores implant therapy in medically compromised patients from the perspective of private practice, addressing decision making under uncertainty, risk mitigation, and when restraint is the most responsible option.
A documented clinical case of a patient with a bleeding disorder illustrates how medical collaboration, planning, and surgical discipline translate evidence into safe outcomes.
A concise summary of recent studies reviews current evidence on implant therapy in compromised populations, emphasizing where data supports treatment, and where caution remains essential.
An infographic based on a real-world study of TiUltra surface implants visualizes outcomes across compromised subpopulations, demonstrating how large-scale, clinical data can inform everyday clinical decisions without oversimplification.
An interview with Dr. Julie Schlosser focuses on patient communication, highlighting how transparency, expectation management, and trust are as critical as surgical expertise when treating medically fragile individuals.
Evidence informs. Judgment decides
No dataset, however large, can replace professional judgment. Evidence informs treatment; it does not dictate it. Final responsibility always rests with the healthcare provider and should be guided by the patient’s medical history, preferences, and overall well-being.
In some situations, the most responsible decision may result in refraining from implant therapy altogether. Supporting clinicians with rigorous science, honest communication, and realistic expectations, while acknowledging the realistic challenges of clinical practice is central to patient outcomes. Ultimately, responsible progress in implant dentistry requires integrity over certainty or preference.
Ethics, evidence, and responsibility
A commitment to ethics in implant dentistry is inseparable from how evidence is generated and communicated. At Nobel Biocare, this means investing in large and real-world studies, designed to reflect everyday clinical conditions rather than idealized scenarios. Such studies acknowledge biological variability, clinician judgment, and the realities of complex patient care, providing data that supports safe decision making rather than absolute claims.
This approach stands in stark contrast to practices sometimes encountered in the field. I have seen clinicians approached by marketing brochures from other market leaders claiming exaggerated surgical outcomes supported by a single small study of fewer than twenty patients.
Presenting such data as definitive is not only scientifically misleading; it places an unfair burden on clinicians, creates unrealistic expectations, and risks clinical decisions being driven by marketing rather than medicine.
In my view, this is where ethics must draw a clear line. Responsible innovation does not amplify the most favorable numbers, but it contextualizes them. It respects uncertainty, scale, and limitations, and recognizes that protecting patients ultimately begins with protecting clinicians from claims that oversimplify the complex biological realities of human beings.